TY - JOUR
T1 - Micrornas in endometrial cancer
T2 - Recent advances and potential clinical applications
AU - Yanokura, Megumi
AU - Banno, Kouji
AU - Iida, Miho
AU - Irie, Haruko
AU - Umene, Kiyoko
AU - Masuda, Kenta
AU - Kobayashi, Yusuke
AU - Tominaga, Eiichirou
AU - Aoki, Daisuke
PY - 2015/2/2
Y1 - 2015/2/2
N2 - Endometrial cancer is a common malignant gynecological tumor, but there are few biomarkers that are useful for early and accurate diagnosis and few treatments other than surgery. However, use of microRNAs (miRNAs) that induces gene downregulation in cells may permit effective and minimally invasive diagnosis and treatment. In endometrial cancer cells, expression levels of miRNAs including miR-185, miR-210 and miR-423 are upregulat-ed and those of miR-let7e, miR-30c and miR-221 are downregulated compared to normal tissues, and these miRNAs are involved in carcinogenesis, invasion and metastasis. miRNAs with expression changes such as miR-181b, miR-324-3p and miR-518b may be used as prognostic biomarkers and transfection of miR-152 may inhibit cancer growth. However, most current studies of miRNAs are at a basic level and further work is needed to establish clinical applications targeting miRNAs.
AB - Endometrial cancer is a common malignant gynecological tumor, but there are few biomarkers that are useful for early and accurate diagnosis and few treatments other than surgery. However, use of microRNAs (miRNAs) that induces gene downregulation in cells may permit effective and minimally invasive diagnosis and treatment. In endometrial cancer cells, expression levels of miRNAs including miR-185, miR-210 and miR-423 are upregulat-ed and those of miR-let7e, miR-30c and miR-221 are downregulated compared to normal tissues, and these miRNAs are involved in carcinogenesis, invasion and metastasis. miRNAs with expression changes such as miR-181b, miR-324-3p and miR-518b may be used as prognostic biomarkers and transfection of miR-152 may inhibit cancer growth. However, most current studies of miRNAs are at a basic level and further work is needed to establish clinical applications targeting miRNAs.
KW - Biomarker
KW - Endometrial cancer
KW - MicroRNA
KW - OncomiR
KW - Tumor suppressor miR
UR - http://www.scopus.com/inward/record.url?scp=84928236867&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928236867&partnerID=8YFLogxK
U2 - 10.17179/excli2014-590
DO - 10.17179/excli2014-590
M3 - Review article
AN - SCOPUS:84928236867
SN - 1611-2156
VL - 14
SP - 190
EP - 198
JO - EXCLI Journal
JF - EXCLI Journal
ER -